

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL FINANCIAL INFORMATION OF CR BOYA BIO-PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2022

On 24 March 2023, CR Boya Bio-pharmaceutical released its annual report for the year ended 31 December 2022.

China Resources Boya Bio-pharmaceutical Group Company Limited (華潤博雅生物製藥集團股份有限公司) (“**CR Boya Bio-pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of CR Boya Bio-pharmaceutical are listed on the Shenzhen Stock Exchange. As of the date of this announcement, China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) indirectly holds approximately 29.28% of the total share capital and approximately 40.59% voting rights in the total share capital of CR Boya Bio-pharmaceutical, and therefore, CR Boya Bio-pharmaceutical is a subsidiary of the Company.

On 24 March 2023, CR Boya Bio-pharmaceutical released its annual report for the year ended 31 December 2022 (the “**CR Boya Bio-pharmaceutical Audited Annual Financials**”). Set out below are the key financial information of the CR Boya Bio-pharmaceutical Audited Annual Financials:

	As of 31 December 2022 <i>(RMB)</i> (audited)	As of 31 December 2021 <i>(RMB)</i> (audited)	Increase <i>(%)</i>
Total assets	8,033,175,408.45	7,621,775,902.48	5.40%
Net assets attributable to shareholders of the listed company	7,185,634,486.84	6,829,074,243.57	5.22%
	For the year ended 31 December		
	2022 <i>(RMB)</i> (audited)	2021 <i>(RMB)</i> (audited)	Increase/ decrease <i>(%)</i>
Revenue	2,758,701,315.10	2,650,528,421.87	4.08%
Net profit attributable to the shareholders of the listed company	432,197,553.97	344,528,999.52	25.45%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	392,124,538.69	293,492,852.21	33.61%
Net cash flow from operating activities	596,437,198.85	1,345,377,085.21	-55.67%
Basic earnings per share <i>(RMB/share)</i>	0.86	0.79	8.86%
Diluted earnings per share <i>(RMB/share)</i>	0.86	0.79	8.86%
Weighted average return on net asset <i>(%)</i>	6.18%	7.83%	-1.65 percentage point

As determined by the board of directors of CR Boya Bio-pharmaceutical, CR Boya Bio-pharmaceutical proposed to distribute a cash dividend of RMB2.00 (inclusive of tax) for every 10 shares to all shareholders of CR Boya Bio-pharmaceutical based on the total share capital of CR Boya Bio-pharmaceutical on the date of equity distribution registration. Such proposal shall be submitted for shareholders’ approval at CR Boya Bio-pharmaceutical’s 2022 annual general meeting.

The CR Boya Bio-pharmaceutical Audited Annual Financials have been prepared and audited in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to CR Boya Bio-pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Boya Bio-pharmaceutical Audited Annual Financials, please refer to the annual report for the year ended 31 December 2022 published by CR Boya Bio-pharmaceutical on the website of the Shenzhen Stock Exchange (www.szse.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Hong Kong, 27 March 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.